AOD-9604: What Happened in the Weight-Loss Trials?
AOD-9604 has been studied for obesity, but online claims often leave out the details. This guide explains the human evidence and its limits.
MOTS-c appears in claims about weight loss, energy and exercise. Much of the research involves cells, animals or measurements of the peptide the body makes naturally. That is different from showing that an injected product helps people lose weight safely.

MOTS-c is a small peptide linked to mitochondria, the parts of cells involved in producing energy. Scientists are studying its role in metabolism and how the body responds to stress and exercise.
The name appears in two quite different settings. Researchers measure the MOTS-c that the body produces naturally. Online sellers also use the name for products intended to be injected. Evidence about the first does not establish that the second is a safe or useful treatment.
A substance can have an important role in the body without becoming a suitable medicine when extra amounts are given. Researchers still need to establish what a manufactured product does, how it behaves and whether its benefits outweigh its risks.
The Care Pharmacy does not offer MOTS-c. The research discussed here should not be treated as advice to buy it or use it for weight loss.
A study published in the Journal of Clinical and Translational Endocrinology compared naturally occurring MOTS-c levels in 22 lean adults and 32 adults with obesity who were due to have bariatric surgery.
Levels in the blood were higher in the group with obesity. In a smaller follow-up group of ten people, those levels did not change significantly six months after surgery, despite weight loss.
This was a study of measurements and associations. It did not give people MOTS-c as a weight-loss treatment. It cannot tell us whether injecting it helps someone lose weight or improves their health.
It also cautions against a simple story that people with obesity must be “missing” this peptide and need it replaced. The body is more complicated than that. An association may reflect an underlying condition, a response to it or several factors acting together.
The authors describe their study as preliminary and exploratory. Larger, independent studies are needed before such measurements could be used confidently in clinical care.
A 2021 study in Nature Communications measured MOTS-c in healthy young men before and after exercise on a stationary bicycle. It found increases in naturally occurring levels. The same paper also included experiments involving cells and mice.
These parts of the study answer different questions. Measuring what happens after people exercise is not the same as testing an injection in people. Giving a compound to mice and measuring their performance is not evidence that it can replace exercise in humans.
Another human exercise study examined circulating mitochondrial-derived peptides after endurance and resistance exercise. Its findings were about the body’s response to activity, rather than a prescribed MOTS-c treatment.
So the phrase “exercise peptide” can be misleading if it suggests the benefits of moving more can be obtained from a vial. The human evidence described here does not establish that.
Animal and cell studies can be valuable. They help researchers work out which ideas deserve further testing. But people differ from laboratory animals in ways that affect treatment response, metabolism and safety.
The important distinction is not whether a study is interesting. It is what question the study can answer.
Natural levels measured in people: these studies can show whether levels vary with a condition or activity. They cannot show that taking extra peptide treats the condition.
A compound given to mice: this can show effects in that animal experiment. It cannot establish an effective, safe treatment for people.
A human treatment trial: this can show the benefits and harms of the particular treatment tested. It cannot establish the same result for a different compound or an unverified product.
A useful weight-management trial would need an appropriate comparison, meaningful follow-up and clear reporting of side effects and people who stop treatment. A promising laboratory mechanism cannot replace that work.
No. CB4211 is a modified compound developed from MOTS-c research. It should not be treated as another name for the body’s own MOTS-c or for every product advertised online.
In results announced by its developer in 2021, an early human study of CB4211 examined safety and tolerability, with exploratory measures of liver markers, glucose and weight. The announcement described a trend towards lower body weight after four weeks.
An early, short study of a different compound cannot establish lasting weight loss from MOTS-c injections. A trend in an exploratory outcome also needs more evidence before it can become a reliable treatment claim.
If a website uses the CB4211 study to sell MOTS-c, it is reasonable to ask whether the product and the outcome being advertised were actually tested. Similar names or a shared research origin do not make the evidence interchangeable.
There is not enough reliable human treatment evidence to give a dependable side-effect rate or a safe self-treatment schedule. Missing reports of harm are not proof that a product is safe.
The US Food and Drug Administration’s 2026 scientific assessment highlights gaps in human safety and effectiveness evidence for MOTS-c-related substances. It also raises concerns about confirming exactly what a product contains, impurities in the peptide and potential immune reactions.
This is a US scientific review, not UK prescribing guidance. It is useful for understanding the evidence gaps, but it does not tell a UK patient how to obtain or use the compound.
Online products add questions about identity, strength, sterility and storage. A certificate claiming high purity does not establish all of those things, and it does not demonstrate that a product causes worthwhile weight loss.
We do not supply MOTS-c or offer it through our consultation. If you have already used a product and feel unwell, contact a healthcare professional and provide the product details. Do not assume that a substance described as natural cannot cause harm.
Those concerns deserve proper assessment. Persistent tiredness should not automatically be labelled a mitochondrial problem or a peptide deficiency on the basis of an online article.
For weight management, the NHS information on overweight and obesity explains support with eating, activity, medicines and specialist services. A clinician can help you consider which options are relevant to your health.
If you are considering private prescription treatment, tell the prescriber about your current medicines, medical conditions and any products bought online. Ask what follow-up is included, how side effects are handled and when progress will be reviewed.
You do not need to understand every new peptide name before seeking help. The assessment should help you choose appropriate care from treatments that can actually be offered, with an explanation of both the potential benefit and the limitations.
The evidence reviewed here does not establish MOTS-c injections as an effective weight-loss treatment. Natural-level studies, animal work and trials of different compounds should not be combined into that claim.
No. A trial record describes research plans. Results need to be reported and assessed before conclusions about benefit and harm can be drawn.
No. MOTS-c is a different peptide with a different research history. It should not be described as equivalent to a licensed GLP-1 treatment.
No. The Care Pharmacy does not offer MOTS-c. Our weight-loss consultation assesses whether currently offered prescription treatment is suitable for you.
If you would like help choosing a weight-loss treatment, complete our online consultation. Our prescriber will review your health and current medicines to assess whether treatment is suitable.
This guide gives general information. Ask a qualified healthcare professional about your own treatment.
Prescription medicines require a clinical assessment. The clinician may recommend a different treatment or an in-person appointment.
Mohammed Ismail Lakhi, MPharm, is the Superintendent Pharmacist at The Care Pharmacy. He leads clinical governance and is registered with the General Pharmaceutical Council, registration number 2072815.
Medically reviewed by
Superintendent Pharmacist
AOD-9604 has been studied for obesity, but online claims often leave out the details. This guide explains the human evidence and its limits.
CJC-1295 and ipamorelin are often discussed together. Evidence for each substance should not be confused with evidence for the combination.
The clinical use of tesamorelin is often confused with general fat-loss claims. This guide explains the distinction and the limits of the evidence.
Can you get Wegovy on the NHS in Scotland? See how advice differs for injections and tablets and what to ask your local health board.
Can you get Wegovy on the NHS in Wales? Learn what Level 3 weight management means and how to ask your local health board about a referral.
Looking into Wegovy in Guildford? See how to ask about a specialist NHS referral and where to find local weight management support in Surrey.